赛升药业(300485.SZ)：控股子公司拥有治疗流感类产品

Group 1 - The core viewpoint of the article is that Sai Sheng Pharmaceutical (300485.SZ) has indicated through its investor interaction platform that its subsidiary possesses products for treating influenza, but the revenue from these products constitutes a small portion of its main business income [1] - The company emphasizes that the use of its influenza-related products must adhere to medical advice [1] - Investors are advised to be cautious regarding investment risks associated with the company's influenza products due to their limited contribution to overall revenue [1]